Gefitinib
- Strength
- 250 mg/1
- Form
- Tablet, Coated
- Class
- Kinase Inhibitor
Ingenus Pharmaceuticals, LLC
Gefitinib
Listed by Qilu Pharmaceutical Co., Ltd.
- Strength
- 250 mg/1
- Form
- Tablet, Coated
- Route
- Oral
- Class
- Kinase Inhibitor
What it contains
- Gefitinib 250 mg/1
FDA record
| Dosage form | Tablet, Coated |
|---|---|
| Route | Oral |
| Drug class | Kinase Inhibitor |
| Approval route | ANDA — approved generic |
| NDC code | 67184-0531 |
| FDA application | ANDA211591 |
| RxNorm concept | 349472 |
| Package sizes listed | 3 |
| Marketed since | February 2023 |
Other products containing Gefitinib
See allSame active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.
Gefitinib
- Strength
- 250 mg/1
- Form
- Tablet, Film Coated
- Class
- Kinase Inhibitor
Natco Pharma USA LLC
Gefitinib
- Strength
- 250 mg/1
- Form
- Tablet, Film Coated
- Class
- Kinase Inhibitor
Teva Pharmaceuticals, Inc.
IRESSA
Gefitinib
- Strength
- 250 mg/1
- Form
- Tablet, Coated
- Class
- Kinase Inhibitor
AstraZeneca Pharmaceuticals LP
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.